// App-Quantinova.ai

163 : A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Researchers

Presenter

  • Dong-Wook Kim

Principal Investigators

  • John F. DiPersio

  • Daniel J. DeAngelo

  • Elisabetta Abruzzese

  • Delphine Rea

  • Michele Baccarani

  • Martin C Muller

  • Carlo Gambacorti-Passerini

  • Stephane Wong

  • Stephanie Lustgarten

  • Victor M. Rivera

  • Maritza Lienlaf

  • Tim Clackson

  • Christopher D. Turner

  • Frank G Haluska

  • Francois Guilhot

  • Michael W. Deininger

  • Andreas Hochhaus

  • Timothy Hughes

  • John M Goldman

  • Neil Shah

  • Hagop M Kantarjian

  • Philipp le Coutre

  • Ron Paquette

  • Charles Chuah

  • Franck E Nicolini

  • Jane Apperley

  • H. Jean Khoury

  • Moshe Talpaz

Medical Centers

  • Department of Histopathology, Imperial College London, London, United Kingdom

  • Pierre Benite, Centre Hospitalier Lyon Sud, Pierre Benite, France

  • Universitatsklinikum Jena, Jena, Germany

  • Institute of Pathology, Charite Universitatsmedizin Berlin, Berlin, Germany

  • Inserm CIC 1402, CHU de Poitiers, Poitiers, France

  • Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea,

  • Singapore General Hospital, Duke-NUS Graduate Medical School, Singapore, Singapore

  • H. Lee Moffitt Cancer Center & Imperial College, Department of Haematology, Hammersmith Hospital, London, United Kingdom

  • Adult hematology department, Hopital Saint-Louis, APHP, Paris, France

  • Ospedale S. Eugenio, Rome, Italy

  • Universitatsmedizin Mannheim, III. Med. Klinik, Mannheim, Germany

  • Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy

  • Dept. of Hematology, Universita Milano Bicocca and S. Gerardo Hospital, Monza, Italy

  • Institute of Medicine and Veterinary Science, Adelaide, Australia

Locations

  • Republic of South Korea

  • Italy

  • Singapore

  • Germany

  • United Kingdom

  • Australia

  • France

Companies

  • ARIAD Pharmaceutical

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Thrombocytopenia

  • Pancreatitis

  • Philadelphia chromosome–positive (Ph+) ALL

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

Drug/Treatment

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • open label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved